Abstract
There is a consensus that previous difficulties encountered in U.S. clinical trials of NCT resulted from the use of inorganic compounds showing no tumor selectivity, and the use of thermal neutron beams which are known to have poor penetration in tissue (HVL ≈ 1.8 cm). Consequently, normal surface tissues were over-exposed, while viable tumor remained at depth. Since then, these problems have been largely circumvented through the development of epithermal neutron beams with better tissue penetration, and the synthesis of various boronated biomolecules which demonstrate tumor selectivity.KeywordsNeutron BeamBoron Neutron Capture TherapyTherapeutic GainEffective Dose RateBoron HydrideThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
